Skip to main content

Tempest Therapeutics, Inc 8-K, filed Nov 12, 2026

Tempest Therapeutics, Inc. (TPST)

8-K 2026-11-12 For: 2026-11-11
View Original
Added on November 12, 2026

About this 8-K

Tempest Therapeutics, Inc filed this 8-K on November 12, 2026, reporting on events of November 11, 2026.

Tempest Therapeutics exercised its option on November 11, 2026 to license Senlang’s CD7-targeted lentiviral in vivo CAR-T platform worldwide, excluding China, after encouraging preliminary results in 13 relapsed or refractory multiple myeloma patients. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits